Trial Profile
Phase II/III Study of the Efficacy and Safety of Macuclear MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 24 Apr 2014
Price :
$35
*
At a glance
- Drugs MC 1101 (Primary)
- Indications Dry age-related macular degeneration
- Focus Therapeutic Use
- Sponsors MacuCLEAR
- 24 Apr 2014 New trial record